Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “Alexion beat both earnings estimates and sales estimates in the fourth quarter. Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. However, the company relies heavily on Soliris for growth and sales of the same will be impacted increased ALXN1210 trials. Pricing is also projected to hit revenues by 3% in 2018. Shares of the company have underperformed the industry over a year. Among new products, the company redefined its strategy for Kanuma as the drug lagged expectations. Meanwhile, in order to focus better in core areas, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma.”
A number of other research analysts have also recently issued reports on ALXN. Piper Jaffray Companies reissued an “overweight” rating and issued a $170.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Stifel Nicolaus decreased their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Royal Bank of Canada lifted their price objective on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $169.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, one has given a hold rating and twenty-one have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $152.77.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 3.33% and a return on equity of 1.36%. The company had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. During the same period in the previous year, the business earned $1.26 earnings per share. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. analysts predict that Alexion Pharmaceuticals will post 5.87 EPS for the current year.
In related news, SVP Heidi L. Wagner sold 1,774 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $206,333.94. Following the transaction, the senior vice president now owns 47,212 shares in the company, valued at $5,491,227.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the transaction, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,930 shares of company stock worth $3,378,199. 4.35% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in ALXN. Delpha Capital Management LLC acquired a new position in Alexion Pharmaceuticals in the fourth quarter valued at $102,000. Valeo Financial Advisors LLC acquired a new position in Alexion Pharmaceuticals in the third quarter valued at $147,000. Dupont Capital Management Corp acquired a new position in Alexion Pharmaceuticals in the third quarter valued at $156,000. BT Investment Management Ltd acquired a new position in Alexion Pharmaceuticals in the third quarter valued at $165,000. Finally, Beacon Investment Advisory Services Inc. acquired a new position in Alexion Pharmaceuticals in the third quarter valued at $201,000. Institutional investors and hedge funds own 94.01% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/alexion-pharmaceuticals-alxn-downgraded-to-sell-at-zacks-investment-research.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.